Author: aweinsoff@channelchek.com

Release – CoreCivic Announces 2025 Fourth Quarter Earnings Release and Conference Call DatesEmpty heading

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CXW

January 6, 2026

PDF Version

BRENTWOOD, Tenn., Jan. 06, 2026 (GLOBE NEWSWIRE) — CoreCivic, Inc. (NYSE: CXW) (“CoreCivic”) announced today that it will release its 2025 fourth quarter financial results after the market closes on Wednesday, February 11, 2026. A live broadcast of CoreCivic’s conference call will begin at 10:00 a.m. central time (11:00 a.m. eastern time) on Thursday, February 12, 2026.

To participate via telephone and join the call live, please register in advance. Upon registration at https://register-conf.media-server.com/register/BId7159f6814fc440f9348e9f8e6ec91f1, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique passcode.

Participants may access the audio-only webcast of the conference call from the Company’s website at www.corecivic.com under the “Events & Presentations” section of the “Investors” page. A replay of the webcast will be available for seven days.

About CoreCivic

CoreCivic is a diversified, government-solutions company with the scale and experience needed to solve tough government challenges in flexible, cost-effective ways. We provide a broad range of solutions to government partners that serve the public good through high-quality corrections and detention management, a network of residential and non-residential alternatives to incarceration to help address America’s recidivism crisis, and government real estate solutions. We are the nation’s largest owner of partnership correctional, detention and residential reentry facilities, and one of the largest operators of such facilities in the United States. We have been a flexible and dependable partner for government for more than 40 years. Our employees are driven by a deep sense of service, high standards of professionalism and a responsibility to help government better the public good. Learn more at www.corecivic.com.

Contact:Investors: Jeb Bachmann – Managing Director, Investor Relations – (615) 263-3024
 Media: Steve Owen – Vice President, Communications – (615) 263-3107

Release – First Phosphate Announces Initial Payment Under Long-Term Offtake Agreement for Phosphate Concentrate

Posted on by aweinsoff@channelchek.com

Research News and Market Data on FRSPF

January 06, 2026 7:11 AM EST | Source: First Phosphate Corp.

Saguenay, Quebec–(Newsfile Corp. – January 6, 2026) – First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce an initial payment under an amendment made to its existing, long-term phosphate concentrate offtake agreement in the form of letter of intent (the “LOI”) with an existing partner (the “Purchaser”).

The Purchaser has agreed to provide a lump-sum pre-payment (the “Lump-sum pre-payment”) equivalent to US $530,000 to First Phosphate to assist the Company in advancing the Bégin-Lamarche phosphate mining project to a feasibility study and an eventual production decision.

First Phosphate completed a Preliminary Economic Assessment on its Bégin-Lamarche phosphate project on December 4, 2024, which recommended, among other things, additional drilling and exploration work to convert certain inferred mineral resources to indicated mineral resources and certain indicated mineral resources into measured mineral resources. First Phosphate is currently in the process of completing a 30,000-metre drill program, which is expected to be completed by April 2026, to finalize the geological model relative to its mineral resources upon which a decision will be made with respect to proceeding with a feasibility study. If First Phosphate decides not to advance to a feasibility study or makes a negative production decision, the Lump-sum pre-payment shall be refundable to the Purchaser.

In other news, Under the collaboration agreement signed on April 9, 2024, the Company has issued 240,132 shares to Pekuakamiulnuatsh First Nation for the exploration and development expenditures undertaken by the Company on the First Nation’s lands in calendar 2025.

Qualified Person

The scientific and technical disclosure for First Phosphate included in this news release has been reviewed and approved by Gilles Laverdière, P.Geo. Mr. Laverdière is Chief Geologist of First Phosphate and a Qualified Person under National Instrument 43-101 – Standards of Disclosure of Mineral Projects (“NI 43-101”).

About First Phosphate Corp.

First Phosphate (CSE: PHOS) (OTCQX: FRSPF) (FSE: KD0) is a mineral exploration, development and cleantech company dedicated to examining and ultimately building and onshoring a vertically integrated mine-to-market lithium iron phosphate (LFP) battery supply chain for North America. Target markets include energy storage, data centers, robotics, mobility and national security.

First Phosphate’s flagship Bégin-Lamarche Property in Saguenay-Lac-Saint-Jean, Quebec, Canada is a North American rare igneous phosphate resource yielding high-purity phosphate with minimal impurities.

Media & Investor Contact:

Bennett Kurtz
Chief Financial Officer
bennett@firstphosphate.com
Tel: +1 (416) 200-0657

Investor Relations: investor@firstphosphate.com
Media Relations: media@firstphosphate.com
Website: www.FirstPhosphate.com

Follow First Phosphate:

X: https://x.com/FirstPhosphate
LinkedIn: https://www.linkedin.com/company/first-phosphate

-30-

Forward-Looking Information and Cautionary Statements

This release includes certain statements that may be deemed “forward-looking information.” Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In particular, this press release contains forward-looking information relating to, among other things: receipt by the Company of the lump-sum pre-payment and the use of the lump-sum pre-payment proceeds; the timeline for completion of, and results from the current drill program; the parties entering into a definitive agreement and the terms of such agreement; and the Company’s plans for building and onshoring a vertically integrated mine-to-market LFP battery supply chain for North America. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include development and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. These statements are based on a number of assumptions including, among other things, assumptions regarding general business and economic conditions; there being no significant disruptions affecting the activities of the Company or inability to access required project inputs; permitting and development of the projects being consistent with the Company’s expectations; the accuracy of the current mineral resource estimates for the Company and results of metallurgical testing; certain price assumptions for P2O5 and Fe2O3; inflation and prices for Company project inputs being approximately consistent with anticipated levels; the Company’s relationship with First Nations and other Indigenous parties remaining consistent with the Company’s expectations; the Company’s relationship with other third party partners and suppliers remaining consistent with the Company’s expectations; and government relations and actions being consistent with Company expectations. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. The Company does not assume any obligation to update or revise its forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law. All forward-looking information contained in this release is qualified by these cautionary statements.

info

Source: First Phosphate Corp.

SKYX Provides Corporate Update Including $9.5 Million in Recent Investment from its Leading Investors as it Continues to Grow its Market Penetration

Posted on by aweinsoff@channelchek.com

Research News and Market Data on SKYX

SKYX Board Member Converted an $835,000 Convertible Note at $2.20 per share

SKYX is in Process of Expanding its AI Ecosystem Program and AI Future Offerings

SKYX Announced Launch of its Patented Advanced SKYFAN and Turbo Heater in U.S. Leading Retailer Target, as well as into the Canadian Market in addition to its E-Commerce Platform with 60 Websites

Driven by Strong Demand, Management Expects to Announce Additional Launches of its SKYFAN and Turbo Heater in January at Several Other Leading U.S. Retailers and Big Box Chains

The Company Anticipates the Winter Launch of its SKYFAN & Turbo Heater Will Advance its Path to Cash-Flow Positive

SKYX Continues its Growth and Expects to Deploy over 60,000 of its Products into Homes/Units by the End of Q1 2026 through Retail and Pro Segments

Management Expects to Secure Additional Significant Business Opportunities in 2026

Following SKYX’s Successful Demonstration of its Technologies during a Marriott Hotel Renovation Company Expects to Significantly Expand its Hotel Segment in 2026

SKYX Revenues Increased for 7 Consecutive Comparable Quarters from Q1 2024 Through Q3 2025 with $19M in Q1/24, $21M in Q2/24, $22M in Q3/24, $23M in Q4/24, $20M in Q1/25, $23M in Q2/25 and $24M in Q3/25

SKYX’s Safety Code Standardization Team is Continuing to Progress and is Receiving Significant Support from a Prominent Leader with its Government Safety Organization Process for Safety Mandatory Standardization in Homes and Buildings of its Ceiling Outlet/Receptacle Technology

SKYX Will Supply its Technologies to Two Key Projects in Austin Texas 278 Units, and San Antonio Texas 340 Units, Built by Prominent Developers Landmark Companies, SKYX is Expected to Deploy Over 25,000 Units of its Advanced and Smart Plug & Play Technologies to The Projects

SKYX’s Major Collaboration with the Mixed-Use Smart City Development in Miami is Expected to Deploy over 500,000 Units of its Advanced and Plug & Play Smart Home Technologies; The Smart City Project Has Expanded from a $3 Billion to a $4 Billion Project

SKYX Will Be Launching a New AI Driven Software for its E-commerce Platform of 60 Websites Which is Expected to Increase its Conversion Rate and Sales Up To 30%; The AI-Native E-Commerce Platform is Designed to Elevate B2B and B2C Experiences through its Innovative and Smart Product Line

SKYX’s Technologies Expansion Provides Additional Opportunities for Future Recurring Revenues Through Interchangeability, Upgrades, AI Services, Monitoring and Subscriptions, Among Others

MIAMI, Jan. 05, 2026 (GLOBE NEWSWIRE) — SKYX Platforms Corp. (NASDAQ: SKYX) (d/b/a SKYX Technologies) (the “Company” or “SKYX”), a highly disruptive platform technology company with over 100 pending and issued patents globally and over 60 lighting and home décor websites, with a mission to make homes and buildings become safe and smart as the new standard, today provides a corporate update including $9.5 million in recent investment from its leading investors as it continues to grow its market penetration.

Highlights, Recent and Future Events

  • As of September 30, 2025, Company reported $13 million in total cash, cash equivalents, restricted cash, and receivables.
  • Company has recently raised $9.5 million in additional capital from several of its leading shareholders.
  • Company continues to leverage its cash position through its e-commerce platform of 60 websites among other methods including support from leading strategic investors and insiders.
  • Management believes it has sufficient cash to achieve its goals including being cash flow positive.
  • SKYX has recently extended and converted $13.5 million in notes coming due with maturity out to 5 years until 2030.
  • SKYX entered into an agreement with Global Ventures Group, a leading U.S. and international real estate development firm, marking a significant step in SKYX’s global expansion strategy.
  • Pursuant to the agreement, Global Ventures Group plans to deploy SKYX’s smart technologies into tens of thousands of homes and hotel rooms in that region and is expected to supply hundreds of thousands of units of its advanced and smart home technologies to projects across the Middle East, including developments in Saudi Arabia and Egypt.
  • The Company entered a major collaboration with a mixed-use smart city development in the heart of Miami, now expanded to a $4 billion project. SKYX is expected to deploy over 500,000 units of its advanced and plug & play smart home technologies.
  • SKYX announced it will be launching a new AI driven software for its e-commerce platform of 60 websites expected to increase its conversion rate and sales up to30%. The AI-native e-commerce platform is designed to elevate B2B and B2C experiences through its innovative and smart product line.
  • SKYX announced it will provide over 25,000 units of its Advanced and Smart Plug & Play products in two projects in the Austin and San Antonio, Texas led by prominent developers Landmark Companies.
  • Company is collaborating with Home Depot and Wayfair on its Advanced and Smart Plug & Play products for both retail and professional segments. SKYX’s product offering will include a variety of its advanced and Smart Plug & Play products including Retrofit Kits, Smart Light Fixtures, Smart Ceiling Fans, Ceiling Outlet Receptacles, Recessed Lights and more.
  • Marriott hotel chain owner, The Shaner Group, led a $16.5 million preferred round to date. The Shaner Group is an owner, and developer of more than 70 hotels worldwide.
  • SKYX has successfully demonstrated its technology during a Marriott Hotel renovation, incorporating its advanced and smart plug & play technologies, including ceiling lighting, recessed lights, downlights, wall lights, EXIT, and EMERGENCY lights, plug-in LED backlight mirrors among others.
  • SKYX revenues increased for 7 prior period comparable quarters from Q1 2024 through Q3 2025 with $19M in Q1/24, $21M in Q2/24, $22M in Q3/24, $24M in Q4/24, $20M in Q1/25, $23M in Q2/25 and $24M in Q3/25.
  • Management is expecting to secure additional significant business opportunities in 2026.
  • SKYX continues its growth and expects to deploy over 60,000 of its products into homes/units by the end of Q1 2026 through retail and pro segments.
  • The Company secured U.S. and global strategic manufacturing partnerships with premier manufacturers including U.S., Vietnam, Taiwan, China, and Cambodia.

Safety Standardization Mandatory Code / Insurance Specification and Recommendation:

  • SKYX’s Safety Code Standardization Team is receiving support from a new significant prominent leader with its government safety agency’s process for a safety mandatory standardization of its electrical ceiling outlet/receptacle technology.
  • SKYX’s code team is led by industry veterans Mark Earley, former head of the National Electrical Code (NEC), and Eric Jacobson, former President and CEO of the American Lighting Association (ALA). The Company’s safety Code Standardization team believes it will garner assistance from additional safety organizations with its code mandatory safety standardization efforts based on the product’s significant safety aspects. Mr. Earley and Mr. Jacobson were instrumental in numerous code and safety changes in both the electrical and lighting industries. Both strongly believe that, considering the Company’s standardization progress including its product specification approval voting for by ANSI / NEMA (American National Standardization Institute / National Electrical Manufacturers Association) and being voted into 10 segments in the NEC Code Book, it has met the necessary safety conditions for becoming a ceiling safety standardization requirement for homes and buildings.
  • With respect to insurance companies, the Company strongly believes its products can save insurance companies many billions of dollars annually by reducing fires, ladder falls, and electrocutions among other things. Management expects that once it completes an entire range and variations of its safe advanced plug & play products it will start being recommended by insurance companies.

About SKYX Platforms Corp.

As electricity is a standard in every home and building, our mission is to make homes and buildings become safe-advanced and smart as the new standard. SKYX has a series of highly disruptive advanced-safe-smart platform technologies, with over 100 U.S. and global patents and patent pending applications. Additionally, the Company owns over 60 lighting and home decor websites for both retail and commercial segments. Our technologies place an emphasis on high quality and ease of use, while significantly enhancing both safety and lifestyle in homes and buildings. We believe that our products are a necessity in every room in both homes and other buildings in the U.S. and globally. For more information, please visit our website at https://skyplug.com/ or follow us on LinkedIn.

SKYX’s technologies provide opportunities for recurring revenues through interchangeability, upgrades, AI services monitoring, and subscriptions. Company is focused on the “Razor & Blades” model and its product range includes its advanced ceiling electrical outlet (Razor) and its advance and smart home plug & play products (Blades) including its advance and smart home plug & play platform products, lighting, recessed lights, down lights, EXIT signs, emergency lights, ceiling fans, chandeliers/pendants, holiday/kids/themes lights, indoor/outdoor wall lights among other. Company’s plug & play technology enables an installation of lighting, fans, and smart home products in high-rise buildings and hotels within days rather than months.

Company’s total addressable market (TAM) in the U.S. is roughly $500 billion with over 4.2 billion ceiling applications in the U.S. alone. Expected revenue streams from retail and professional segments include product sales, royalties, licensing, subscription, monitoring, and sale of global country rights.

Forward-Looking Statements

Certain statements made in this press release are not based on historical facts, but are forward-looking statements. These statements can be identified by the use of forward-looking terminology such as “aim,” “anticipate,” “believe,” “can,” “could,” “continue,” “estimate,” “expect,” “evaluate,” “forecast,” “guidance,” “intend,” “likely,” “may,” “might,” “objective,” “ongoing,” “outlook,” “plan,” “potential,” “predict,” “probable,” “project,” “seek,” “should,” “target” “view,” “will,” or “would,” or the negative thereof or other variations thereon or comparable terminology, although not all forward-looking statements contain these words. These statements reflect the Company’s reasonable judgment with respect to future events and are subject to risks, uncertainties and other factors, many of which have outcomes difficult to predict and may be outside our control, that could cause actual results or outcomes to differ materially from those in the forward-looking statements. Such risks and uncertainties include statements relating to the Company’s ability to successfully launch, commercialize, develop additional features and achieve market acceptance of its products and technologies and integrate its products and technologies with First-party platforms or technologies; the Company’s efforts and ability to drive the adoption of its products and technologies as a standard feature, including their use in homes, hotels, offices and cruise ships; the Company’s ability to capture market share; the Company’s estimates of its potential addressable market and demand for its products and technologies; the Company’s ability to raise additional capital to support its operations as needed, which may not be available on acceptable terms or at all; the Company’s ability to continue as a going concern; the Company’s ability to execute on any sales and licensing or other strategic opportunities; the possibility that any of the Company’s products will become National Electrical Code (NEC)-code or otherwise code mandatory in any jurisdiction, or that any of the Company’s current or future products or technologies will be adopted by any state, country, or municipality, within any specific timeframe or at all; risks arising from mergers, acquisitions, joint ventures and other collaborations; the Company’s ability to attract and retain key executives and qualified personnel; guidance provided by management, which may differ from the Company’s actual operating results; the potential impact of unstable market and economic conditions, including recent measures adopted by the federal government, on the Company’s business, financial condition, and stock price; and other risks and uncertainties described in the Company’s filings with the Securities and Exchange Commission, including its periodic reports on Form 10-K and Form 10-Q. There can be no assurance as to any of the foregoing matters. Any forward-looking statement speaks only as of the date of this press release, and the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by U.S. federal securities laws.

Non-GAAP Financial Measures

Management considers earnings (loss) before interest, taxes, depreciation and amortization, or EBITDA, as adjusted, an important indicator in evaluating the Company’s business on a consistent basis across various periods. Due to the significance of non-recurring items, EBITDA, as adjusted, enables management to monitor and evaluate the business on a consistent basis. The Company uses EBITDA, as adjusted, as a primary measure, among others, to analyze and evaluate financial and strategic planning decisions regarding future operating investments and potential acquisitions. The Company believes that EBITDA, as adjusted, eliminates items that are not part of the Company’s core operations, such as interest expense and amortization expense associated with intangible assets, or items that do not involve a cash outlay, such as share-based payments and non-recurring items, such as transaction costs. EBITDA, as adjusted, should be considered in addition to, rather than as a substitute for, pre-tax income (loss), net income (loss) and cash flows used in operating activities. This non-GAAP financial measure excludes significant expenses that are required by GAAP to be recorded in the Company’s financial statements and is subject to inherent limitations. Investors should review the reconciliation of this non-GAAP financial measure to the comparable GAAP financial measure. Investors should not rely on any single financial measure to evaluate the Company’s business.

Investor Relations Contact:

Jeff Ramson

PCG Advisory

jramson@pcgadvisory.com

Release – Nicola Mining And Blue Lagoon Receive First Payment For Gold And Silver Under Long Term Partnership

Posted on by aweinsoff@channelchek.com

Research News and Market Data on HUSIF

January 5, 2026

News Releases

VANCOUVER, B.C, January 5, 2026 – Nicola Mining Inc. TSX:V: NIM (the “Company” or “Nicola Mining”) is pleased to announce that it and Blue Lagoon Resources (CSE: BLLG) (“Blue Lagoon”) have sold US$1.0 million gold and silver to Ocean Partners UK Limited[1] (“Ocean Partners”).  The Company is also pleased to announce that Blue Lagoon continues to provide steady shipments since the commencing of gold and silver mill feed hauling, as announced on December 1, 2025[2].  The two parties had previously announced[3]a commitment to a long term partnership[4].

Peter Espig, CEO of Nicola, commented, “Nicola is very excited to work closely with Blue Lagoon as the two companies mutually ramp up production and revenues, amidst strong precious metal prices.  Blue Lagoon’s management has done an incredible job in spearheading the project through permitting and mine development to becoming a producer”.

Qualified Person

Cameron Lilly, P. Eng., the Company’s Mill Manager, is the Qualified Person as defined by National Instrument 43-101 – Standards of Disclosure for Mineral Projects and supervised the preparation of, and has reviewed and approved, the technical information in this release.

About Nicola Mining

Nicola Mining Inc. is a junior mining company listed on the Exchange and Frankfurt Exchange that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia It has signed Mining and Milling Profit Share Agreements with high grade gold projects. Nicola’s fully permitted mill can process both gold and silver mill feed via gravity and flotation processes.

The Company owns 100% of the New Craigmont Project, a high-grade copper property, which covers an area of over 10,800 hectares along the southern end of the Guichon Batholith and is adjacent to Highland Valley Copper, Canada’s largest copper mine. The Company also owns 100% of the Treasure Mountain Property, which is a fully-permitted high grade silver mine and includes 30 mineral claims and a mineral lease, spanning an area exceeding 2,200 hectares.

On behalf of the Board of Directors

“Peter Espig”  
Peter Espig
CEO & Director

For additional information

Contact:  Peter Espig
Phone: (778) 385-1213
Email: info@nicolamining.com
URL: www.nicolamining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

[1] Ocean Partners operates in several countries throughout the world.  Ocean Partners maintains a strong global network of relationships and contacts in the base metal mining and smelting sector.

[2] News Release:  December 1, 2025 Link

[3] Nicola Mining News Release dated June 23, 2025

[4] Blue Lagoon’s News Release dated September 29, 2025:  Link

Release – The Oncology Institute Announces Addition of Board Member Mark Stolper

Posted on by aweinsoff@channelchek.com

Research News and Market Data on TOI

Jan 05, 2026

PDF Version

CERRITOS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI), one of the largest value-based oncology groups in the United States, today announced that Mark Stolper has joined the Board of Directors, effective January 2, 2026. Mr. Stolper brings significant public markets, financial and operational leadership experience to The Oncology Institute’s board. Mr. Stolper serves as Executive Vice President and Chief Financial Officer of RadNet, Inc. (NASDAQ: RDNT), a position he has held since 2004. Mr. Stolper has also been a member of the Board of Directors of various publicly traded and privately held healthcare companies, including 21st Century Oncology Holdings, Inc., which at the time was one of the nation’s leading radiation and medical oncology companies.

“We are very pleased to have a seasoned public company CFO like Mark join our board,” said Anne McGeorge, Chairman of the Board of The Oncology Institute. “Mark brings tremendous experience in capital markets, fundraising strategies, strategic financial planning and payor strategy that will be invaluable to TOI in our next phase of growth.”

“I am very excited to join The Oncology Institute’s Board of Directors,” commented Mr. Stolper. “The Company’s mission to provide leading-edge, cost-effective cancer care to improve outcomes and streamline the patient journey is critically important at this time in healthcare. I truly believe that TOI is poised for continued growth and profitability in the coming years.”

About The Oncology Institute
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better. For more information, visit www.theoncologyinstitute.com

Contacts

Media

The Oncology Institute, Inc.
marketing@theoncologyinstitute.com

Investors

ICR Healthcare
TOI@icrhealthcare.com

Release – Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA Meeting

Posted on by aweinsoff@channelchek.com

Research News and Market Data on GYRE

January 5, 2026

PDF Version

  • Gyre Pharmaceuticals completed a Pre-NDA meeting with China’s CDE, which agreed that the existing Phase 3 clinical data support a conditional approval filing for Hydronidone and priority review eligibility, subject to formal approval.
  • Gyre Pharmaceuticals plans to submit an NDA in the first half of 2026 and conduct a confirmatory clinical trial to support full approval in China.

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) — Gyre Therapeutics, Inc. (Gyre or the Company) (Nasdaq: GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic disease, today announced that its majority-owned subsidiary in China, Gyre Pharmaceuticals Co., Ltd. (Gyre Pharmaceuticals), completed a Pre–New Drug Application (Pre-NDA) communication meeting with the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) regarding Hydronidone, the Company’s first-in-class anti-fibrotic therapy.

During the meeting, Gyre Pharmaceuticals and the CDE reached consensus that existing Phase 3 clinical data for Hydronidone, based on histologic improvement in liver fibrosis as measured by the Ishak fibrosis score, are generally supportive of submission of a conditional approval NDA for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis, including early (compensated) cirrhosis. The CDE further indicated that Hydronidone meets the criteria for inclusion in China’s Priority Review and Approval Program for Innovative Drugs, subject to formal filing, acceptance and regulatory review.

The NMPA previously granted Hydronidone Breakthrough Therapy Designation in March 2021, recognizing its potential to address a serious condition with significant unmet medical need. This designation supports eligibility for priority review, which is intended to facilitate an accelerated regulatory review process for innovative therapies.

As previously disclosed on May 22, 2025, Gyre reported topline results from its Phase 3 trial in CHB-associated liver fibrosis demonstrating that Hydronidone met its primary endpoint, with 52.85% of treated patients achieving ≥1-stage fibrosis regression at Week 52, compared with 29.84% in the placebo group (p=0.0002), based on centralized, blinded Ishak histologic assessment. The trial also achieved a key secondary endpoint evaluating improvement in liver inflammation without fibrosis progression and demonstrated a favorable safety profile consistent with prior clinical experience.

As part of the agreed regulatory pathway, the Company plans to conduct an additional confirmatory clinical trial (referred to as a Phase 3c trial in China) designed to evaluate liver-related clinical outcomes to support potential conversion from conditional approval to regular approval.

The Company currently expects to submit an NDA for conditional approval of Hydronidone in the first half of 2026, subject to final data readiness and applicable regulatory procedures.

“Hydronidone addresses a significant unmet medical need in patients with CHB-associated liver fibrosis, for whom there are currently no approved anti-fibrotic therapies,” said Ping Zhang, Interim Chief Executive Officer of Gyre. “We are encouraged by the positive and constructive Pre-NDA dialogue with the CDE and the alignment achieved on a clear regulatory pathway. This milestone reflects the strength of our Phase 3 clinical data and supports our plans to advance Hydronidone toward conditional approval in China.”

About Hydronidone

Hydronidone is a novel, orally administered anti-fibrotic agent designed to target key liver fibrosis pathways. It attenuates hepatic stellate cell activation and fibrogenesis, at least in part, by suppressing TGF-β1-induced signal transduction, including reduced p38γ phosphorylation and upregulated Smad7 expression. This upregulation of Smad7 subsequently leads to downregulation of TGF-βRI and inhibition of Smad2/3 activation, thereby disrupting canonical TGF-β/Smad signaling and reducing fibrotic gene expression in HSCs.

The drug has completed Phase 3 clinical evaluation in China for CHB-associated liver fibrosis, including early (compensated) cirrhosis, and is being evaluated for its potential applicability across additional fibrotic diseases in region-specific development programs.

About the CHB Fibrosis Market in China

CHB-associated liver fibrosis represents a significant unmet medical need in China. According to China’s national hepatitis B serological survey and internal epidemiological modeling, it is estimated that 60–70 million people in China are infected with hepatitis B virus, of whom approximately 14.7 million are diagnosed. Among these patients, an estimated 2.6 million have diagnosed, compensated, clinically significant liver fibrosis (F2–F4), excluding decompensated cirrhosis, and may be eligible for anti-fibrotic intervention.

About Gyre Pharmaceuticals

Gyre Pharmaceuticals is a commercial-stage biopharmaceutical company committed to the research, development, manufacturing and commercialization of innovative drugs for organ fibrosis. Its flagship product, ETUARY® (pirfenidone capsule), was the first approved treatment for IPF in the PRC in 2011 and has maintained a prominent market share (2024 net sales of $105.8 million). In addition, Gyre Pharmaceuticals’ pipeline includes Hydronidone, a structural analogue of pirfenidone, which demonstrated statistically significant fibrosis regression after 52 weeks of treatment in a pivotal Phase 3 clinical trial in CHB-associated liver fibrosis in the PRC. Hydronidone received Breakthrough Therapy designation by the NMPA Center for Drug Evaluation in March 2021. Gyre Pharmaceuticals is also developing treatments for PD, RILI with or without immune-related pneumonitis, COPD, PAH and ALF/ACLF. As of the third quarter of 2025, Gyre Therapeutics owns a 69.7% equity interest in Gyre Pharmaceuticals.

About Gyre Therapeutics

Gyre Therapeutics is a biopharmaceutical company headquartered in San Diego, CA, primarily focused on the development and commercialization of Hydronidone for liver fibrosis including MASH in the U.S. Gyre’s strategy builds on its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis. In the PRC, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, including therapeutic expansions of ETUARY, and development programs for F573, F528, and F230.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, are forward-looking statements, including statements concerning: the expectations regarding Gyre’s research and development efforts and the timing of expected clinical readouts and regulatory filings, including the anticipated timing of the filing of Gyre’s NDA with the NMPA for the conditional approval of Hydronidone for the treatment of CHB-associated liver fibrosis and early cirrhosis and the initiation of the confirmatory Phase 3c clinical trial of Hydronidone to support full approval in China. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation: Gyre’s ability to execute on its clinical development strategies; positive results from a clinical trial may not necessarily be predictive of the results of future or ongoing clinical trials; the timing or likelihood of regulatory filings and approvals; competition from competing products; the impact of general economic, health, industrial or political conditions in the United States or internationally; the sufficiency of Gyre’s capital resources and its ability to raise additional capital; supply chain and distribution delays and challenges. Additional risks and factors are identified under “Risk Factors” in Gyre’s Annual Report on Form 10-K for the year ended December 31, 2024 filed on March 17, 2025 and in other filings with the Securities and Exchange Commission.

Gyre expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

For Investors:
David Zhang, Chief Business Officer
david.zhang@gyretx.com 

Release – InPlay Oil Corp. Confirms Monthly Dividend for January 2026

Posted on by aweinsoff@channelchek.com
InPlay Oil logo (CNW Group/InPlay Oil Corp.)

Research News and Market Data on IPOOF

CALGARY AB, Jan. 2, 2026 /CNW/ – InPlay Oil Corp. (TSX: IPO) (OTCQX: IPOOF) (“InPlay” or the “Company”) is pleased to confirm that its Board of Directors has declared a monthly cash dividend of $0.09 per common share payable on January 30, 2026, to shareholders of record at the close of business on January 15, 2026. The monthly cash dividend is expected to be designated as an “eligible dividend” for Canadian federal and provincial income tax purposes.

About InPlay Oil Corp.

InPlay is a junior oil and gas exploration and production company with operations in Alberta focused on light oil production. The company operates long-lived, low-decline properties with drilling development and enhanced oil recovery potential as well as undeveloped lands with exploration possibilities. The common shares of InPlay trade on the Toronto Stock Exchange under the symbol IPO and the OTCQX Exchange under the symbol IPOOF.

www.inplayoil.com 

SOURCE InPlay Oil Corp.

For further information please contact: Doug Bartole, President and Chief Executive Officer, InPlay Oil Corp., Telephone: (587) 955-0632; Darren Dittmer, Chief Financial Officer, InPlay Oil Corp., Telephone: (587) 955-0634

Release – Aurania Directors Receive Stock Options in Lieu of Fees

Posted on by aweinsoff@channelchek.com

Research News and Market Data on AUIAF

January 02, 2026 7:00 AM EST | Source: Aurania Resources Ltd.

Toronto, Ontario–(Newsfile Corp. – January 2, 2026) – Aurania Resources Ltd. (TSXV: ARU) (OTCQB: AUIAF) (FSE: 20Q) (“Aurania” or the “Company”) announces that its Board of Directors have agreed to receive their quarterly director fees in the form of stock options in lieu of cash for the fourth quarter of 2025. For more information, see press releases dated March 31, 2025, July 1, 2025 and October 1, 2025.

On December 31, 2025, each director was granted 34,500 stock options at an exercise price of $0.175 in lieu of their director fees for the fourth quarter of 2025. An aggregate of 138,000 stock options was granted. All such stock options will be exercisable for a period of three years from the date of grant and vested immediately upon grant. In the event a director intends to exercise such stock options, such director shall be solely responsible for paying the entirety of the exercise price.

About Aurania
Aurania is a mineral exploration company engaged in the identification, evaluation, acquisition, and exploration of mineral property interests, with a focus on precious metals and critical energy in Europe and abroad.

Information on Aurania and technical reports are available at www.aurania.com and www.sedarplus.ca, as well as on Facebook at https://www.facebook.com/auranialtd/, Twitter at https://twitter.com/auranialtd, and LinkedIn at https://www.linkedin.com/company/aurania-resources-ltd-.

For further information, please contact:

Carolyn Muir
VP Corporate Development & Investor Relations
Aurania Resources Ltd.
(416) 367-3200
carolyn.muir@aurania.com		 

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

info

Source: Aurania Resources Ltd.

Release Nicola Mining Announces Strategic Investment from Ocean Partners

Posted on by aweinsoff@channelchek.com

Research News and Market Data on HUSIF

December 29, 2025 9:00 AM EST | Source: Nicola Mining Inc.

Vancouver, British Columbia–(Newsfile Corp. – December 29, 2025) – Nicola Mining Inc. (TSXV: NIM) (the “Company” or “Nicola Mining“) is pleased to announce an additional investment from Ocean Partners UK Limited[1] (“Ocean Partners“), which has agreed to participate in a strategic non-brokered private investment of $1,000,000 to strengthen the Company’s balance sheet as it prepares to uplist onto NASDAQ in Q1 of 2026.

The Company will issue 1,111,112 units (each a “Unit“) at a price of $0.90 per Unit for gross proceeds of up to $1,000,000 (the “Offering“).

Each Unit will consist of one common share of the Company (each, a “Share“) and one transferable common share purchase warrant (each, a “Warrant“). Each Warrant will entitle the holder to purchase one additional Share at a price of $1.10 per Share for a period of three years following the closing of the Offering (the “Closing“). The expiry of the Warrants may be accelerated if the closing price of the Company’s common shares on the TSX Venture Exchange (the “Exchange”) is $1.70 or greater for a minimum of ten consecutive trading days, provided that a notice of acceleration is issued in accordance with the terms of the Warrants.

All securities issued in connection with the Offering will be subject to a statutory holding period expiring four months and one day after closing of the Offering. Completion of the Offering is subject to the approval of the Exchange. Any participation by insiders in the Offering will constitute a related party transaction under Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions (“MI 61-101”) but is expected to be exempt from the formal valuation and minority shareholder approval requirements of MI 61-101.

The aggregate gross proceeds from the sale of the Offering will be used for general working capital.

None of the securities sold in connection with the Offering will be registered under the United States Securities Act of 1933, as amended, and no such securities may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements. This news release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Strategic Advisor – Mr. Rahim Kassim-Lakha of Blue Sail Capital

Nicola is also pleased to announce the appointment of Rahim Kassim-Lakha, founder and CEO of Blue Sail Capital, as Strategic Advisor. With nearly 30 years of investing in global i capital markets and M&A experience, Mr. Kassim-Lakha has a proven track record in raising capital and structuring transactions. He has held senior roles at Fidelity Capital and U.S. Global Investors, where he managed over US$1 billion across three award-winning funds. As Strategic Advisor he will provide guidance on capital markets strategy and corporate development opportunities as Nicola advances its projects.

About Nicola Mining

Nicola Mining Inc. is a junior mining company listed on the Exchange and Frankfurt Exchange that maintains a 100% owned mill and tailings facility, located near Merritt, British Columbia It has signed Mining and Milling Profit Share Agreements with high grade gold projects. Nicola’s fully permitted mill can process both gold and silver mill feed via gravity and flotation processes.

The Company owns 100% of the New Craigmont Project, a high-grade copper property, which covers an area of over 10,800 hectares along the southern end of the Guichon Batholith and is adjacent to Highland Valley Copper, Canada’s largest copper mine. The Company also owns 100% of the Treasure Mountain Property, which is a fully-permitted high grade silver mine and includes 30 mineral claims and a mineral lease, spanning an area exceeding 2,200 hectares.

On behalf of the Board of Directors

“Peter Espig“

Peter Espig
CEO & Director

For additional information

Contact: Peter Espig
Phone: (778) 385-1213
Email: info@nicolamining.com
URL: www.nicolamining.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

[1] Ocean Partners operates in several countries throughout the world. Ocean Partners maintains a strong global network of relationships and contacts in the base metal mining and smelting sector.

info

Source: Nicola Mining Inc.

Release – Nutriband Inc. Signs Agreement to Sell Majority Stake of Subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio

Posted on by aweinsoff@channelchek.com

Research News and Market Data on NTRB

Earthvision Bio, is currently developing and commercializing its line of sustainable products developed by Dr. Gordon Moore, the founder of Intel, and Dr. Hans Franke, ex-chairman for Chevron Europe

Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition

The expected closing date for the transaction is Dec 31, 2025.

Orlando, Fla. – Dec 29, 2025 – Nutriband Inc. (NASDAQ: NTRB) (NASDAQ: NTRBW), today announced that it has signed an agreement to sell a 90% interest in its subsidiary Pocono Pharmaceutical for $5M USD to EarthVision Bio.

Earthvision Bio has developed and are commercializing a new category of sustainable products created by Dr. Gordon Moore, the founder of Intel (NASDAQ: INTC), and Dr. Hans Franke, who was board chairman for Chevron Europe. The Company has developed a sustainable way to replace plastic, molded fiber, wood, and paper products with Earth-friendly alternatives.

Nutriband Inc. Shareholders will retain 10% of the shareholding in Earth Vision Bio following the acquisition.

Nutriband inc. will use the proceeds from the sale of Pocono Pharma towards its continued development of AVERSA Fentanyl which has the potential to be the world’s first and only abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach annual US sales of $80 million to $200 million.

About AVERSA™ Abuse-Deterrent Transdermal Technology

Nutriband’s AVERSA™ abuse-deterrent transdermal technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential. The AVERSA™ abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse, including opioids and stimulant drugs, while making sure that these drugs remain accessible to those patients who really need them. The technology is covered by a broad intellectual property portfolio with patents granted in the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia.

About Nutriband Inc.

We are primarily engaged in the development of a portfolio of transdermal pharmaceutical products. Our lead product under development is an abuse-deterrent fentanyl patch incorporating our AVERSA™ abuse-deterrent technology. AVERSA™ technology can be incorporated into any transdermal patch to prevent the abuse, misuse, diversion, and accidental exposure of drugs with abuse potential.

The Company’s website is www.nutriband.com. Any material contained in or derived from

 

Forward-Looking Statements

Certain statements contained in this press release, including, without limitation, statements containing the words ‘’believes,” “anticipates,” “expects” and words of similar import, constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve both known and unknown risks and uncertainties. The Company’s actual results may differ materially from those anticipated in its forward-looking statements as a result of a number of factors, including those including the Company’s ability to develop its proposed abuse-deterrent fentanyl transdermal system and other proposed products, its ability to obtain patent protection for its abuse technology, its ability to obtain the necessary financing to develop products and conduct the necessary clinical testing, its ability to obtain Federal Food and Drug Administration approval to market any product it may develop in the United States and to obtain any other regulatory approval necessary to market any product in other countries, including countries in Europe, its ability to market any product it may develop, its ability to create, sustain, manage or forecast its growth; its ability to attract and retain key personnel; changes in the Company’s business strategy or development plans; competition; business disruptions; adverse publicity and international, national and local general economic and market conditions and risks generally associated with an undercapitalized developing company, as well as the risks contained under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in the Company’s periodic and current reports on Form 10-K, Forms 10-Q and 8-K and the Company’s other filings with the Securities and Exchange Commission. Except as required by applicable law, we undertake no obligation to revise or update any forward-looking statements to reflect any event or circumstance that may arise after the date hereof.

Release – Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

Posted on by aweinsoff@channelchek.com

Research News and Market Data on CVKD

PONTE VEDRA, FL / ACCESS Newswire / December 29, 2025 / Every industry has its forgotten corners. In anticoagulation, those corners turned into entire neighborhoods. For years, the field centered itself around convenience drugs built for broad populations and clean commercial lines. Warfarin stayed because it always had. DOACs (direct oral anticoagulants) rose in use because they were easier to manage. The patients who were harder to serve, the ones with unstable renal function or dangerous immune responses, got pushed to the edges of the conversation.

Cadrenal Therapeutics (NASDAQ:CVKD) did not follow the herd. It walked straight into the clinical territory everyone else avoided. Not because it was simple. Not because it was fashionable. But because improving outcomes for the most fragile patients is where real therapeutic change begins. The future of anticoagulation will not be won by a slightly more polished version of what already exists. It will be won by companies willing to rebuild the pieces that Big Pharma stopped trying to fix.

That is where Cadrenal stands today. The company is not chasing the old model. It is reconstructing the parts of anticoagulation where the stakes are the highest and the options are the weakest. It is doing it with intention, with discipline, and with a portfolio engineered to solve the hardest problems first. That is how you build something lasting in a field that has not changed meaningfully in decades.

Tecarfarin Sets the Foundation for a Different Kind of Platform

Cadrenal’s Phase 3-ready lead asset, tecarfarin, makes the company’s strategy instantly clear. The drug is designed to serve patients who fall outside the tolerances of traditional anticoagulation. End-stage kidney disease. Dialysis transitions. Complex cardiac burdens that magnify every downside of existing drugs. These are not the easy cases. They are the cases where outcomes hinge on control, predictability, and the ability to adjust therapy without destabilizing the entire system.

Tecarfarin was built precisely for that environment. It is engineered to offer stability where warfarin wobbles. It maintains therapeutic levels without the wild swings that plague standard vitamin K antagonists. It avoids the renal clearance issues that make DOACs dangerous for kidney-impaired patients. And it retains reversibility, one of the most clinically valuable yet commercially underappreciated traits in anticoagulation.

This is not a niche convenience drug. It is the cornerstone of a platform built for patients who cannot rely on yesterday’s tools. Tecarfarin is what happens when a company decides to re-engineer the roots of a category rather than dress up the branches.

The eXIthera XIa Acquisition Expanded Cadrenal From Chronic to Acute Care

The company’s next major move signaled its intent to play across the full spectrum of anticoagulation. Cadrenal acquired a Factor XIa inhibitor portfolio from eXIthera, giving it a second mechanistic approach that fits squarely into acute hospital care. Factor XIa is one of the most promising targets in modern hematology because it reduces clot formation without triggering the same bleeding penalties clinicians struggle with today.

This acquisition expanded Cadrenal’s relevance beyond chronic conditions and into the point-of-care environment, where hospitals need safer and more predictable anticoagulation. A single admission involving a bleeding complication or a clot formation event can cost tens of thousands of dollars and derail treatment plans. Hospitals know this. Physicians know this. Cadrenal clearly knows it too.

By integrating Factor XIa into its strategy, the company now spans both sides of the anticoagulation lifecycle. Tecarfarin stabilizes long-term risk. Factor XIa manages acute risk. Very few small companies get that kind of mechanistic breadth. Cadrenal built it in a single step.

VLX-1005 Pushed Cadrenal Into High-Stakes Immune-Mediated Territory

Then Cadrenal raised the stakes again. The company acquired VLX-1005, a first-in-class 12-LOX inhibitor in Phase 2 development for heparin-induced thrombocytopenia. HIT is one of the most dangerous complications in hospital medicine. It turns a routine anticoagulant like heparin into a trigger for catastrophic clotting and platelet collapse. Doctors do not get much time to react once HIT is in motion.

VLX-1005 comes with Orphan Drug and Fast Track designations, which immediately elevate its strategic value. This program moves Cadrenal into an area where treatment options are scarce, the stakes are immediate, and even incremental improvements matter. It also proves that the company is building a portfolio, not a single drug story.

With VLX-1005 in the mix, Cadrenal now sits on three distinct scientific pillars. Vitamin K antagonism with tecarfarin. Factor XIa inhibition for acute care. 12-LOX inhibition for immune-mediated thrombosis. This is not an accidental collection of assets. It is a purpose-built response to the biggest failures of today’s anticoagulation toolkit.

A Pipeline Built for the Problems That Actually Matter

Cadrenal is rebuilding the parts of anticoagulation that the rest of the industry quietly accepted as unsolvable. It focuses on the patients who create the most clinical and economic strain. It is expanding across chronic, acute, and immune-mediated conditions without drifting away from its central theme.

The company does not look like a microcap when you study the configuration of its pipeline. It looks like a specialty anticoagulation house in its early chapters. Investors will eventually catch up, but the company is not waiting for them. The work is already underway. The blueprint is already visible. And the parts of anticoagulation that everyone else has given up on are finally being rebuilt.

About Cadrenal Therapeutics, Inc.
Cadrenal Therapeutics, Inc. is developing differentiated products that bridge critical gaps in current acute and chronic anticoagulation management for rare and high-risk patient populations. It currently has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT, tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. For more information, visit https://www.cadrenal.com/ and connect with the Company on LinkedIn.

Safe Harbor

Any statements in this press release about future expectations, plans, and prospects, as well as any other statements regarding matters that are not historical facts, may constitute “forward-looking statements.” The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potentially,” “predict,” “project,” “should,” “target,” “will,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements include statements regarding advancing VLX-1005 for the treatment of HIT; continuing to advance novel therapeutics to treat or prevent thrombosis in high-risk patients; the emerging data from VLX-1005 suggesting meaningful potential to improve patient outcomes while maintaining a favorable safety profile; VLX-1005 being a compelling strategic addition to Cadrenal’s pipeline; the payment to Veralox of milestone payments contingent upon the achievement of certain future clinical and regulatory milestones as well as royalties on global sales of the acquired assets upon future commercialization; the structure and terms of the agreement enabling Cadrenal to allocate capital to advancing the clinical development of VLX-1005; and developing transformative therapeutics to overcome the limitations of current anticoagulation therapy. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including the ability to advance the clinical development of VLX-1005 for the treatment of HIT; the ability to continue to advance novel therapeutics to treat or prevent thrombosis in high-risk patients; the ability to successfully complete clinical trials on time and achieve desired results and benefits as expected; the ability to obtain regulatory approvals for commercialization of product candidates or to comply with ongoing regulatory requirements and the other risk factors described in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, and the Company’s subsequent filings with the Securities and Exchange Commission, including subsequent periodic reports on Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. Any forward-looking statements contained in this press release speak only as of the date hereof and, except as required by federal securities laws, the Company specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events, or otherwise.

Accuracy & Disclosure Statement: Hawk Point Media Group, LLC (HPM) has been retained by IR Agency, Inc. to provide press releases, editorial insights, and digital media production for Cadrenal Therapeutics. This content is sponsored. For services rendered from December 12, 2025 through December 16, 2025, extended to December 31, 2025, HPM has been compensated ten thousand dollars (USD) via wire transfer for content creation and syndication related to Cadrenal Therapeutics. The information contained herein is based on sources believed to be accurate and reliable at the time of creation, including publicly available filings, company disclosures, and direct website content. This material is provided for informational purposes only and should not be interpreted as investment advice, a recommendation, or an offer to buy or sell any security.

At the time of publication, HPM does not own, buy, sell, or trade securities of the companies covered. However, individuals or organizations that have retained HPM may hold shares of Cadrenal Therapeutics and may sell those shares during the coverage period. Such sales could place downward pressure on the stock price and result in financial loss for investors.

Any reproduction, redistribution, or syndication of this content must include this disclosure in full. This statement is provided in accordance with Section 17(b) of the Securities Act of 1933, the Federal Trade Commission’s Endorsement Guides, and other applicable laws governing sponsored communications and paid investor content.

Contact information for this release: info@hawkpointmedia.com

SOURCE: Cadrenal Therapeutics

Release – Kratos Receives Approximately $30 Million in Air Defense and C5ISR System National-Security-Related Hardware Production Contracts

Posted on by aweinsoff@channelchek.com

Research News and Market Data on KTOS

December 29, 2025

PDF Version

SAN DIEGO, Dec. 29, 2025 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a leader in defense, national security and global markets, announced today that it has recently received approximately $30 million in Air Defense and C5ISR system national-security-related, military-grade custom hardware production contracts. Kratos is an industry leader in the development, engineering, design, and large-scale production of military-grade hardware and integrated systems for missile, radar, counter-UAS, hypersonic, directed energy, satellite communication, and other complex systems. Work performed under the recent contract awards will be performed in secure Kratos manufacturing facilities.

Tom Mills, President of Kratos’ C5ISR Division, said, “Our entire team is honored to have our customers’ confidence in our ability to engage early in the systems’ design phase to collaborate with our customers on system-level engineering and design, provide highly engineered custom systems and solutions, large-scale manufacturing, at an affordable cost, for these urgent, relevant, and mission critical systems. Kratos is the recognized industry leader in delivering military-grade hardware and systems in direct support of America’s National Security requirements.”

Eric DeMarco, President and CEO of Kratos, said, “Delivering relevant, military-grade hardware on time, on schedule, and that works every time is hard, and Kratos’ demonstrated capability to continuously do so is a differentiator for our Company to our customers and partners. Kratos is currently in high volume, mass production on multiple hypersonic, counter-UAS, missile, radar and other systems, and we are proud to be the clear industry leader in our mil-spec hardware areas of expertise.”

Due to competitive, security related and other considerations, no additional information will be provided.

About Kratos Defense & Security Solutions
Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low-cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, advanced vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com.

Notice Regarding Forward-Looking Statements
Certain statements in this press release may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made on the basis of the current beliefs, expectations and assumptions of the management of Kratos and are subject to significant risks and uncertainty. Investors are cautioned not to place undue reliance on any such forward-looking statements. All such forward-looking statements speak only as of the date they are made, and Kratos undertakes no obligation to update or revise these statements, whether as a result of new information, future events or otherwise. Although Kratos believes that the expectations reflected in these forward-looking statements are reasonable, these statements involve many risks and uncertainties that may cause actual results to differ materially from what may be expressed or implied in these forward-looking statements. For a further discussion of risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of Kratos in general, see the risk disclosures in the Annual Report on Form 10-K of Kratos for the year ended December 29, 2024, and in subsequent reports on Forms 10-Q and 8-K and other filings made with the SEC by Kratos.

Press Contact:
Claire Cantrell
claire.cantrell@kratosdefense.com

Investor Information:
877-934-4687
investor@kratosdefense.com

Primary Logo

Source: Kratos Defense & Security Solutions, Inc.

Release – Newsmax Expands in Europe, Mid-East with Major Distribution Deals

Posted on by aweinsoff@channelchek.com

Research News and Market Data on NMAX

December 29, 2025

Carriage Deals With Free TV France, HOT Israel and Primetel Cyprus, Along With a Partnership in Ukraine, Extend Newsmax’s Reach Across Europe and the Mid-East

BOCA RATON, FLORIDA / ACCESS Newswire / December 29, 2025 / Newsmax Inc. (NYSE:NMAX) (“Newsmax” or the “Company”) through its subsidiary Newsmax Broadcasting, today announced a series of multi-year distribution agreements with major TV distributors across Europe and the eastern Mediterranean. These partnerships with Free TV in France, HOT in Israel and Primetel in Cyprus will make the Newsmax channel available to millions of new households and demonstrates the Company’s commitment to delivering independent U.S.-based news to international audiences.

In addition, Newsmax has entered into a brand license agreement to launch early next year a local channel, “Newsmax Ukraine”, available in the Ukrainian language.

New carriage and brand license agreements

  • Free TV (France) – Free TV, one of France’s leading telecommunications providers, has launched Newsmax on channel 351, reaching approximately 3.5 million households. This partnership strengthens Newsmax’s presence in Western Europe and offers French viewers 24/7 access to both U.S. and global news.
  • HOT (Israel) – Newsmax is now available in English on channel 204 through HOT Israel, a major telecommunications and pay TV operator. The launch reaches more than 200,000 subscribers and expands Newsmax’s footprint in a key U.S.-ally market, providing Israeli audiences with access to breaking news, political analysis and cultural coverage.
  • Primetel (Cyprus) – Newsmax has debuted on channel 241 via Primetel, a leading IPTV and telecom provider in Cyprus. Primetel subscribers can access Newsmax’s live news, interviews and talk programming, further strengthening Newsmax’s presence in the eastern Mediterranean region.
  • Newsmax Ukraine – Newsmax has signed a brand license agreement for the launch of Newsmax Ukraine, a localized news channel expected to go live in the first half of 2026. The channel will operate under the Newsmax brand and editorial framework, marking an important step in the Company’s Eastern European growth strategy and its commitment to expanding access to international news in the region.

Newsmax is now available in more than 100 countries across five continents. According to Nielsen, Newsmax is the fourth highest-rated cable news network in the United States, reaching over 40 million Americans through its television channel, streaming services and digital platforms.

About Newsmax

Newsmax Inc. is listed on the NYSE (NMAX) and operates, through Newsmax Broadcasting LLC, one of the nation’s leading news outlets, the Newsmax channel. The fourth highest-rated network is carried on all major pay TV providers. Newsmax’s media properties reach more than 50 million Americans regularly through Newsmax TV, the Newsmax App, its popular website Newsmax.com, and publications such as Newsmax Magazine. Through its social media accounts, Newsmax reaches over 22 million combined followers. Reuters Institute says Newsmax is one of the top U.S. news brands and Forbes has called Newsmax “a news powerhouse.”

For more information, please visit Investor Relations | Newsmax Inc.

Forward-Looking Statements
This communication contains forward-looking statements. From time to time, we or our representatives may make forward-looking statements orally or in writing. We base these forward-looking statements on our expectations and projections about future events, which we derive from the information currently available to us. Forward-looking statements can be identified by those that are not historical in nature. The forward-looking statements discussed in this communication and other statements made from time to time by us or our representatives, may not occur, and actual events and results may differ materially and are subject to risks, uncertainties and assumptions about us. Newsmax does not guarantee future results, performance or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy or completeness of any of these forward-looking statements. Forward-looking statements should not be relied upon as predictions of future events. We are under no duty to update any of these forward-looking statements after the date of this communication to conform our prior statements to actual results or revised expectations, and we do not intend to do so. Factors that may cause actual results to differ materially from current expectations include various factors, including but not limited to the factors set forth in the sections entitled “Risk Factors” in Newsmax’s Annual Report on Form 10-K for the twelve months ended December 31, 2024, Newsmax’s Quarterly Report on Form 10-Q for the three months ended March 31, 2025, and other filings Newsmax makes with the Securities and Exchange Commission. Nothing in this communication should be regarded as a representation by any person that the forward-looking statements set forth herein will be achieved or that any of the contemplated results of such forward-looking statements will be achieved. Undue reliance should not be placed on forward-looking statements in this communication, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein.

Investor Contacts
Newsmax Investor Relations
ir@newsmax.com

SOURCE: Newsmax Inc.

View the original press release on ACCESS Newswire